Melanoma Clinical Trial

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Summary

This clinical trial studies how well an interactive tailored website works in promoting sun protection and skin self-check behaviors in patients with stage 0-III melanoma. An internet-based program may help individuals to perform skin self-checks and engage in sun protection behaviors.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To evaluate the impact of the interactive tailored website (ITW) versus usual care on skin self-examination (SSE) and sun protection behaviors among individuals diagnosed with melanoma.

SECONDARY OBJECTIVES:

I. To examine mediators of the impact of the intervention. The effects of the intervention on SSE and sun protection behaviors will be mediated by melanoma knowledge, self-efficacy for SSE and sun protection behaviors, perceived benefits of SSE and sun protection behaviors, perceived barriers to SSE and sun protection behaviors, and perceived controllability of melanoma.

TERTIARY OBJECTIVES:

I. To examine moderators of the impact of the intervention. To evaluate whether ITW effects are moderated by the following factors: time since diagnosis, disease stage, age, sex, income, education, Internet experience, distress about melanoma, worry about recurrence, and evaluation and usage of the ITW.

OUTLINE:

Phase I: Patients review draft website content materials in a semi-structured format and provide feedback via open- and closed-ended questions for the development, testing, and finalization of ITW.

Phase II: Patients are randomized into 1 of 2 arms.

ARM I: Patients access ITW and complete each module over 30-40 minutes.

ARM II: Patients receive usual care and are then offered ITW.

All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Phase I: Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma
Phase I: From 3-36 months post-surgical treatment
Phase I: Access to the internet
Phase I: Able to speak and read English
Phase I: Able to provide informed consent
Phase II: Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma
Phase II: From 3-24 months post-surgical treatment
Phase II: Not adherent to thorough SSE (i.e., did not check every area of the body at least once during the past 2 months)
Phase II: Not adherent to sun protection recommendations (i.e., mean score < 4 [which corresponds to "often"] on a 5-point scale [from 1 = "never" to 5 = "always"] that assesses the frequency of engaging in four sun protection behaviors)
Phase II: Access to a computer connected to the internet
Phase II: Able to speak and read English
Phase II: Able to provide informed consent

Study is for people with:

Melanoma

Estimated Enrollment:

485

Study ID:

NCT03028948

Recruitment Status:

Completed

Sponsor:

Rutgers, The State University of New Jersey

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08903, United States
University of Virginia
Charlottesville Virginia, 22904, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

485

Study ID:

NCT03028948

Recruitment Status:

Completed

Sponsor:


Rutgers, The State University of New Jersey

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.